{
  "report_rows": [
    {
      "kpi": "New Patient Starts (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~315K vs. cons 304K",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Total Revenue (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$1,305M vs. cons $1,290.5M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Operating EPS (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$0.63 vs. cons $0.609",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY 2026 Revenue (FY 2026)",
      "prediction": "BETTER",
      "answer": "guide ~$5.26B midpoint vs. cons $5,223.9M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY 2026 Gross Margin (FY 2026)",
      "prediction": "UNCHANGED",
      "answer": "guide 63-64% reiterated vs. cons ~63.6%",
      "confidence": "HIGH"
    },
    {
      "kpi": "FY 2026 Operating Margin (FY 2026)",
      "prediction": "UNCHANGED",
      "answer": "guide 23-23.5% reiterated vs. cons ~23.3%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "New Patient Start Trajectory (qualitative, H2 2026)",
      "prediction": "BETTER",
      "answer": "confirm record pace, Prime Therapeutics tailwind, CMS update positive vs. flat consensus assumption",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 5.0,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 3.0,
  "day5_path": "STABILIZE",
  "day5_rationale": "STABILIZE \u2014 modest follow-through from short covering and small estimate revisions; high-run setup limits sustained momentum; gross margin trajectory is the key watch",
  "day5_confidence": "MEDIUM"
}